New Japan Approvals Include Tafinlar, Tagrisso
This article was originally published in PharmAsia News
The latest batch of drug approvals in Japan includes several novel oncology products, some of which have only recently been launched elsewhere, in a sign that applicants and regulators are trying to speed up local access to important new therapies.
You may also be interested in...
Japan Approval Another Boost For Tagrisso in 1L NSCLC
Following a priority review, Japan has approved AstraZeneca’s Tagrisso for the first-line treatment of inoperable or recurrent EGFR mutation-positive NSCLC, further strengthening the drug’s position in this setting.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Leqembi bodes well for Biogen; AbbVie predicts US Humira erosion; Sanofi’s R&D chief moves on; Roche’s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.
Tech Transfer Roundup: MD Anderson, Replay Found Allogeneic TCR-NK Cell Therapy Play Syena
Start-up hopes to bring its first candidate, an NY-ESO-1-targeting off-the-shelf product, into the clinic in Q2. Astex and Cardiff University team up on novel therapies for neurodegenerative disease.